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Abstract
Background: The disappointing results of surgical therapy alone of ductal pancreatic cancer can
only be improved using multimodal approaches. In contrast to adjuvant therapy, neoadjuvant
chemoradiation is able to facilitate resectability with free margins and to lower lymphatic spread.
Another advantage is better tolerability which consecutively allows applying multimodal treatment
in a higher number of patients. Furthermore, the synopsis of the overall survival results of
neoadjuvant trials suggests a higher rate compared to adjuvant trials.
Methods/Design: As there are no prospectively randomised studies for neoadjuvant therapy, the
Interdisciplinary Study Group of Gastrointestinal Tumours of the German Cancer Aid has started
such a trial. The study investigates the effect of neoadjuvant chemoradiation in locally resectable or
probably resectable cancer of the pancreatic head without distant metastasis on median overall
survival time compared to primary surgery. Adjuvant chemotherapy is integrated into both arms.
Discussion: The protocol of the study is presented in condensed form after an introducing survey
on adjuvant and neoadjuvant therapy in pancreatic cancer.
Background
Ductal carcinoma of the head of the pancreas represents a
considerable problem in oncology with a mortality rate of
8–12/100,000 and per year. Pancreatic carcinoma is the
fifth leading cause of cancer death in Germany. For all
stages, 5 year overall survival rate is 6% form en and 3%
for women[1]. Curative (R0-) resection is only possible in
20% of all patients but even then the 5 year overall sur-
vival rate is only 25% – even in cancer centres[2]. Median
overall survival time of 18–25 months after R0-resect5ion
reflects the bad prognosis of this disease[3].
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Surgical therapy
Patients with pancreatic carcinoma who are presented in
surgical departments have tumours that are unresectable
in 70–80% because of locally advanced disease or distant
metastases. Surgery results in about 25% in a palliative sit-
uation (R1-/R2-resection). These patients have no chance
of cure (Tumour Registry of the University Hospitals of
Erlangen and [3]).
The bad prognosis for patients with pancreatic cancer is
caused above all by:
- Early invasion of the mesenteric root and of the central
vessels (superior mesenteric artery and superior
mesenteric vein, portal vein). In spite of resection of infil-
trated vessels by e.g. tangential or segmental portal vein
resection and successive reconstruction, almost all of
these patients will eventually die within a year.
- Frequent and extensive lymphatic metastases in up to
75%. Between 1983 and 1997, 647 patients with ductal
adenocarcinoma of were registered at the registry of the
surgical department of the University of Erlangen. Sur-
vival for patients with stage III (T1-3; N+; UICC 1997) was
3% without adjuvant therapy after 5 years.
This scenario emphasizes that surgical therapy alone is
not sufficient for pancreatic carcinoma and that prospec-
tive investigation of additional modalities is crucial. The
high frequency of local relapse and of distant metastasis is
the main reason for tumour progression. The rate of local
relapse without adjuvant therapy is about 80% [4-6] and
can be reduced to rates up to 26% after adjuvant chemo-
radiation (CRT) [5,7-9].
The rationale of adjuvant therapy is to reduce the rate of
local relapse and distant metastasis. Neoadjuvant CRT can
additionally increase the rate of resections with clear mar-
gins (R0-resection).
Actual assessment of adjuvant therapy
The results of three randomised studies of adjuvant ther-
apy are summarised in table 1[10-12]. In the GITSG trial
the patients were randomised either for 5-fluorouracil (5-
FU) based CRT and sequential weekly 5-FU maintenance
5-FU chemotherapy or for observation[10]. The patients
in the treatment arm had longer survival times compared
to patients with resection only (20 months vs. 11
months). The EORTC randomised in a following larger
phase III study 218 patients with adenocarcinoma of the
pancreas or of the peri-ampullary region either for CRT or
for no further treatment after Whipple's procedure. [11].
In a subgroup analysis the median survival time for
patients with pancreatic carcinoma was 17.1 months for
patients with CRT compared to only 12.6 months after
surgery alone (p = 0.099). Although, the prolongation of
survival after adjuvant therapy did not reach statistic sig-
nificance the EORTC trial confirmed that the survival of
patients without adjuvant therapy is poor (10–12
months).
The ESPAC-1 trial [12,13] included 541 patients and 289
of them were randomised for a 2 × 2 factorial study design
that addressed the patients to the study arms observation,
chemotherapy, CRT or CRT followed by chemotherapy.
CRT consisted in bolus 5-FU and radiotherapy of 40 Gy in
a split course technique. Chemotherapy was given as six
cycles of bolus 5-FU (425 mg/m2) and leukovorin (20
mg/m2) per day for 5 days with repetition after 28 days.
Recently, the results of the ESPAC-1 trial have been
reported with restriction on the patients that had been
randomised to the 2 × 2 factorial study design. [12]. This
analysis showed lower survival for patients after CRT com-
pared to the patients without CRT (15.9 months vs. 17.9
months). Vice versa, patients with chemotherapy had
longer survival in comparison with those who had no
chemotherapy (20.1 months vs. 15.5. months; p = 0.009).
These results question the role of CRT as a component of
adjuvant therapy. The interpretation of the results of the
ESPAC-1 study is very difficult for a number of different
Table 1: Phase III studies of adjuvant 5-fluorouracil based therapy#.
Study year Number of 
patients
Inclusion criteria 
Resection status
5-FU based 
therapy (months)
Follow-up 
(months)
p Preoperative 
diagnostics
Postoperative 
Imaging
Inked 
margin
GITSG-1985 [10] 49 R0 RCT 21.0 10.9 0.005 No No No
EORTC-1999 [11] 114* R0 RCT 17.1 12.6 0.099 No No No
ESPAC-1-2004 [12] 289§ R0 or R1 Cx 21.6 16.9 n.a. No No No
# Median survival rates from three randomised studies in patients with resected pancreatic carcinoma. None of these trials used either high quality 
preoperative imaging to evaluate resectability, or postoperative imaging, to exclude tumour persistence or distant metastasis.
* The EORTC trial comprised 218 patients with periampullary and pancreatic carcinoma. The results shown here are based upon the 114 patients 
with pancreatic carcinoma.
§ 541 patients were included into ESPAC-1, but only 289 were included into 2 × 2 factorial randomisation. Trial arms: observation, chemotherapy, 
chemoradiation, chemoradiation followed by chemotherapy. The table gives the survival rates fort he best treatment arm (chemotherapy) and 
observation.BMC Cancer 2007, 7:41 http://www.biomedcentral.com/1471-2407/7/41
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reasons (cf. the editorial „One lesson to be learned from
this well-intentioned study is that a straightforward anal-
ysis driven by the factorial structure is not always as sim-
ple as it seems“ [14]). Remarkably, the patients of the best
arm of the ESPAC-1 trial have a median survival time
which is identical with the patients form the GITSG trial
that have been achieved two decades earlier.
At the 2005 annual meeting of the American Society of
Clinical Oncology (ASCO) the preliminary results of
another phase III trial (CONKO-001) of adjuvant therapy
has been presented [15,16]. Within six weeks after resec-
tion 386 patients (N+ in 72% and R1 in 18%) were ran-
domised to gemcitabine (179 patients) or observation
(177 patients); 12 patients were excluded. Gemcitabine
was given with 1000 mg/m2 on days 1, 8 and 15 every 4
weeks for 6 months. The primary endpoint was disease
free survival (DFS) and the secondary endpoints overall
survival and toxicity. At the time of analysis 68% of the
patients had progress. Median DFS was significantly dif-
ferent (p < 0.05): after gemcitabine 14.2 months vs. 7.5
months without. Data were not yet ready for analysis of
overall survival. The final results are expected for late
2006.
More knowledge about adjuvant therapy of pancreatic
carcinoma are expected from the currently active studies:
EORTC 40013/22012 (gemcitabine vs. gemcitabine +
CRT + gemcitabine), ESPAC-3 (5-FU vs. gemcitabine),
RTOG (5-FU + CRT + 5-FU vs. Gem + RCT + Gem), CapRI-
study (5-FU vs. CRT with 5-FU/cDDP/IFN-α) [17].
The current situation on adjuvant therapy can be summa-
rized with three aspects: (1) the general impression of ran-
domised studies is that an improvement of the survival
rates of about 10% is realistic. (2) The suitability of DFS
as an endpoint for adjuvant trials is very restricted. Ultra-
sound for follow up (as used in the CONKO-1-study in
week 8. and 16. after surgery) is not able to detect local
recurrence after the abdominal anatomic changes of
Whipple's procedure. Overall survival remains the most
robust endpoint for adjuvant studies. (3) The following
questions remain to be answered by further trials: the type
of adjuvant chemotherapy (5-FU vs. gemcitabine), the
role of adjuvant chemoradiation, performed with modern
standards, the question if patients with R1-resections
necessitate different therapy than patients with R0-resec-
tions, and the evaluation of the value of neoadjuvant
chemoradiation.
Neoadjuvant therapy of pancreatic carcinoma
Neoadjuvant therapy of pancreatic carcinoma is able to
increase the resectability rate with clear margins (R0-resec-
tion)[18,19] and to decrease the rate of local relapse[20].
Additionally, neoadjuvant trials report a decrease of the
rate of metastastic lymph nodes (30–48%)[20,21] com-
pared to initial surgery (60–80%) [2,22-26]. Both effects
improve the prognosis of patients with pancreatic carci-
noma. Furthermore, neoadjuvant therapy is better toler-
ated than adjuvant therapy resulting in a higher number
of patients who will tolerate the intended therapy
(reviewed in [27]): 20% of the initially treated patients are
unresectable intra-operatively. Another 25–50% of the
patients do not receive adjuvant therapy because of insuf-
ficient recovery from surgery or because of patient refusal
of therapy. In total, only 40–60% of primary operated
patients eventually will be administered the intended
therapy. In contrast, complete therapy (neoadjuvant CRT
and resection) can be given in 60–65% of the patients
with tumours estimated to be resectable at diagnosis.
Rapid disease progression is the reason why 20–25% will
not be resected after neoadjuvant CRT. These patients
experience rapid progression because of aggressive
tumour biology not only during or after neoadjuvant CRT
but also after primary resection. In a neoadjuvant concept
they will be spared futile morbidity of Whipple's proce-
dure. Another 20% of the patients are not resected intra-
operatively because of extrapancreatic disease. For the lat-
ter patients optimal therapy for locally advanced pancre-
atic carcinoma has already been given which is
chemoradiation
To date, there is no prospectively randomised phase III-
study for neoadjuvant therapy. Table 2 shows a summary
of the largest published studies. Most of these series are
single institutional ([20,21,28,29]). The largest published
series is from the M.D. Anderson Cancer Centre and
reports on 132 patients who have been treated between
1990 through 1999. A remarkable 88% rate of R0-resec-
tions is well above the results after initial resection.
Median overall survival time of 21 months is excellent in
the light of a 43% rate of vascular resections. After CRT
patients with nodal spread had worse prognosis than
those without nodal spread as well as patients with male
gender in multivariate analysis. The first site of relapse was
exclusively local in 5% of the patients. Another 5% of the
patients had combined local and distal relapse. The rate of
perioperative lethality was not increased (2/132). Further-
more, 4 treatment related deaths occurred as a conse-
quence of gastrointestinal bleedings (3 patients) and after
thrombosis of a reconstructed portal vein (1 patient).
Good response of the tumours at tumour regression grad-
ing correlated with a trend to longer survival.
The correlation between good response and survival was
significant in the Duke University series (1994 and 2004)
where 70/193 patients were resected after CRT. Patients
with good response in tumour regression grading had a
significant prolongation of survival. Furthermore, the his-
tological description of tumour necrosis was a bad prog-B
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Table 2: Selected studies of neoadjuvant chemoradiation.
Study Institution Number of 
patients
Total dose of 
XRT (Gy)
Chemo-therapy (mg/m2)M e d i a n  O S  
(months)
1(2,4,5)-year-
OS-rate (%)
Rate local 
recurrence (%)
Rate of 
resectability (%)
Rate of clear 
resections
Hoffman et al. 1998 [39, 40] 
multi-centric
53 50.4 5-FU/MMC 9.7 all pts
15.7 res
2y: 27 res 24/53 (26 %)
3/24 (13%) res
24/53 (45%) n.a
Snady et al. 2000 [29] Mount Sinai 159
68* (20 res§)
91 adj
54 + 14 Gy 5-FU/cDDP/Streptozotocin 23.6* (32 res)
14.0
1 y: 86*(89)vs.64
2y: 58*(60) vs.32
3y: 27*(40)vs.17
n.a. 20/68 (29%)
-
95% neo
84% adj
Breslin et al. 2001 [20] MDACC 132 45 or 50.4 Gy
or 10 × 3 Gy ± IORT
5-FU, or Tax or Gem 21 1y: 75
2y: 40
5y: 23
8/132 (6%) - 88%
Sasson AR et al.2003 [28] FCCC 116
61 neo
55 adj
50.4 5-FU/MMC or Gem all 18
neo 23
adj 16
n.a. n.a. - 39%
n.a.
n.a.
White et al. 2005 [21] Duke 193
i.p.r.:102
i.l.f.: 91
45 + 5.4 Gy 5-FU or Gem 23
39 i.p.r.
20 i.l.f.
3y: 37 res
5y: 27 res
n.a. 70/193 (36%)
54/102 (53%)
16/91 (18%)
73%
n.a.
n.a.
Abbreviations: 5-FU = 5-fluorouracil; adj = adjuvant therapy; cDDP = cisplatin; FCCC = Fox Chase Cancer Center, Philadelphia, PA; Gem = gemcitabine; Gy = Dose in Gray; i.p.r = initially potentially 
resectable; i.l.f. = initially locally advanced, MDACC = M.D. Anderson Cancer Center Houston, TX; MMC = mitomycin C; n.a. = not available; neo = neoadjuvant; OS = overall survival; res = resected 
patients, RT = radiotherapy; Tax = paclitaxel; vs. = versus. *initially unresectable patients ± resection after chemoradiation; § this study indicates overall survival as explained: (1) patients with chemoradiation 
(2) numbers in brackets: patients with chemoradiation and resection (3) right to 'vs.': patients after primary resection; § numbers in brackets in this row give results of the 20/68 resected patients with RCT.BMC Cancer 2007, 7:41 http://www.biomedcentral.com/1471-2407/7/41
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nostic factor. The median overall survival of 39 months of
patients with primary unresectable tumours who under-
went resection after CRT is remarkable. As in the Houston
series[20] patients without nodal metastasis had longer
survival. The relative low rate of nodal disease (30%) in
comparison with initial resection[2,22-26] allows to
deduct sterilisation of nodes with disease after CRT. It is
also important to acknowledge that resection could be
performed after CRT in 18% of the patients who had ini-
tially unresectable tumours. In a trial published by
Wilkowski et al. this rate was even higher (14/33 patients
= 42%)[30]. This means that resectability needs to be re-
evaluated after CRT.
Median survival of neoadjuvantly treated (n = 61) vs.
adjuvantly treated patients (n = 55) was longer for neoad-
juvantly treated patients in a study from Philadelphia
which compared both approaches (median OS = 23 vs. 16
months)[28]. Positive margins and lymphatic disease had
a significant influence on survival. Another study com-
pared primary surgery (n = 91) of patients with initially
resectable tumours with neoadjuvant CRT of patients with
locally advanced tumours (n = 68). Survival was longer for
patients after CRT with and without subsequent resection
compared to patients with primarily resected tumours
(23.6 vs. 14 months of mOS). Median overall survival was
32 months for 20/68 patients with resection after CRT.
Curative resection (R0) could be increased by 11% as a
consequence of neoadjuvant CRT.
In summary, the value of neoadjuvant CRT can be
described by four short statements:
(1) there are several safe and sufficiently tested schedules
for neoadjuvant CRT. However, gemcitabine containing
schedules probably can achieve a higher rate of pathologic
response compared to 5-FU based protocols[31]. Simulta-
neous CRT with gemcitabine and cisplatin is able to pro-
duce even in locally advanced pancreatic carcinoma good
local response with a high rate of secondary respectability
with good tolerability[30,32,33].
(2) The survival rates of the synopsis of neoadjuvant trials
are longer in comparison with the survival rates after
resection and adjuvant therapy.
(3) The accurate definition of resectability is a prerequisite
for the quality of neoadjuvant studies. Resectability needs
to be based upon pretherapeutic imaging which is prefer-
entially performed by helical CT scanning and the descrip-
tion of the exact extent of vascular involvement [34-36].
(4) Even if pretherapeutic histological proof is not always
possible it can be achieved in a high percentage when
diagnostic and therapeutic disciplines interact closely[37].
Methods/Design
This trial aims to answer the question if neoadjuvant CRT
with gemcitabine and cisplatin can prolong overall sur-
vival of patients with ductal adenocarcinoma of the pan-
creatic head in comparison with primary resected
patients.
The treatment algorithm (Fig. 1) depicts the treatment
flow. Tables 3 and 4 lists all inclusion and exclusion crite-
ria. It is mandatory for inclusion to obtain the histological
proof of diagnosis e.g. via CT guided biopsy or conclusive
brush cytology, and to perform a multi slice CT scan of the
abdomen showing a resectable or probably resectable
tumour [34]. If informed consent has been obtained prior
to surgery, randomization can also be performed intra-
operatively during laparoscopy
Arm A consists of partial (subtotal) duodenopancreatec-
tomy with defined lymphatic dissection followed by adju-
vant chemotherapy.
Arm B consists of neoadjuvant CRT (Fig. 2), followed by
tumour resection and then by adjuvant chemotherapy.
Chemoradiation
Conventional fractionated, 3-d-conformal irradiation is
administered with a total dose of 55.8 Gy (tumour region)
or 50.4 Gy (regional lymph nodes) respectively[38].
Simultaneously gemcitabine (300 mg/m2) and 30–60
minutes later cisplatin (30 mg/m2) or administered on
days 1, 8, 22 and 29 both as a 30 minute IV infusion. Six
weeks after completion of CRT, a restaging CT scan is
scheduled to exclude tumour progress. Thereafter, surgery
is performed.
Surgical therapy
Partial duodenopancreatectomy is done if the tumour
appears to be resectable after laparotomy. The minimal
requirements for surgery are:
• Transsection of the hepatocholedochal duct slightly dis-
tally to the junction of the cystic and the hepatic duct.
• Transsection of the pancreas minimally at the level of
the left edge of the portal vein.
The resection plane of the specimen should be analysed
histologically if possible already at the intraoperative
fresh frozen section. However, it is mandatory to perform
histological analysis of the postoperatively paraffin
embedded tissue to exclude positive margins (R1-resec-
tion).BMC Cancer 2007, 7:41 http://www.biomedcentral.com/1471-2407/7/41
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In both arms, adjuvant chemotherapy for 6 months
according to the protocol of the CONKO-001 study (Neu-
haus et al. 2006 JAMA in press) is recommended.
Quality of life
Evaluation of quality of life is done with a standardized
questionnaire (EORTC QLQ-C30 with additional mod-
ule).
Follow up
Follow up examinations are planned every 3 months fort
he first 2 years after surgery and thereafter every 6 months
for at least 3 years. Examinations consist of a physical
examination, monitoring of the course of CA-19-9 and
ultrasound of the abdomen. Staging is complemented by
CT abdomen and a chest X-ray every 6 months if local or
distant failure is suspected.
Discussion
The trial is carried out as a multi-centre trial with centres
from Germany, Switzerland and Austria. The participating
centres offer all techniques of 3-d-conformal irradiation.
They all perform more than 15 pancreaticoduodenecto-
mies per year, each. Extensive experience in combined
multimodality treatment approaches is provided. There-
fore, all essential requirements to conduct the present
Treatment schedule Figure 1
Treatment schedule.
Table 3: Inclusion criteria
• Histologically proven ductal adenocarcinoma of the pancreatic head (tumours of the pancreatic head right to the left edge of the superior 
mesenteric vein including the uncinate process), stage I- IV A according to UICC 1997. Histological proof should be performed via percutaneous 
CT- or ultrasound guided biopsy (up to 3 attempts) if impossible by endoscopic biopsy or endoscopic cytology (brush cytology with tumour cells).
• No infiltration of extrapancreatic organs with the exception of the duodenum
• pancreatic tumour as imaged in multi slice spiral CT (slice collimation 3 mm) estimated to be resectable or probably resectable by an 
experienced surgeon on the base of the following criteria: vascular involvement ≤ 180° of one of the peripancreatic major vessels (portal vein, 
confluent of superior mesenteric vein and, splenic vein, superior mesenteric artery, celiac trunk with its major branches splenic artery and hepatic 
artery, superior mesenteric vein) (Lu et al., 1997).
• maximally 1 enlarged (> 1 cm) regional lymph node in thin slice spiral CT, without signs of vessel infiltration
• no distant metastasis (in X-ray chest, abdominal CT and laparoscopy)
• no peritoneal spread (laparoscopy prior to randomization is recommended)
• age at treatment initiation minimally 18 years
• Karnofsky performance status ≥ 70 (70 – not capable to work, independent)
• Written informed consent of the patientBMC Cancer 2007, 7:41 http://www.biomedcentral.com/1471-2407/7/41
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study are met at the participating departments. With the
present trial, we aim at improving outcome in patients
with resectable pancreatic adenocarcinoma by adding
neoadjuvant chemoradiation to the current treatment
standard consisting of resection followed adjuvant chem-
otherapy.
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Table 4: Exclusion criteria
• ampullary carcinoma (tumours origination from the ampulla, the papilla or at the junction of the ampulla and the papilla)
• carcinoma of the pancreatic corpus or tail (tumours between the left edge of the superior mesenteric vine and the left edge of the aorta 
respectively between the left edge of the aorta and the splenic hilum)
• Non-ductal adenocarcinoma of the pancreas (e.g. cystadenocarcinoma, neuroendocrine tumours, etc.)
• Tumour specific prior treatment
• Recurrent tumour
• Peritoneal spread
• distant metastasis
• 2 or more enlarged lymph nodes (> 1 cm), with suspicion of metastatic spread based upon morphology in CT scan.
• Infiltration of extrapancreatic organs except of the duodenum
• vascular involvement > 180° of minimally one of the peripancreatic major vessels (portal vein, confluent of V. mesenterica sup. and V. lienalis, A. 
mesenterica superior, coeliac trunk, V. mesenterica superior), stenosis or occlusion of one of the mentioned vessels. Resectability only if vascular 
resection is performed (including portal vein and superior mesenteric vein).
• Prior or synchronous malign neoplasia (Except: non-melanomatous skin cancer and curatively treated carcinoma in situ of the uterine cervix and 
tumour treated by surgery alone with 10 years of disease-free survival)
• Participation at a clinical trial within the last three months prior to inclusion
• Hepatic cirrhosis with platelets < 100 000/mm3 or PTT < 70%
• Serum creatinine > 1.5 mg/dl, creatinine-clearance < 70 ml/min (24 h collection of urine; because of planned chemotherapy with cisplatin)
• Severe cardio-pulmonary concomitant disease (cardiac insufficiency NYHA III/IV, arrhythmia Lown III/IV, pathologic findings at cardiac ultrasound 
(pathologic ejection fraction), respiratory global insufficiency, or any other severe disease that could interfere with complete therapy as rated by the 
surgeons or radiation oncologists who participate in the treatment
• HIV-infection
• pregnancy or insufficient contraception
• Age < 18 years
• Karnofsky performance status < 70
• doubtful understanding or contractual capacity of the patientBMC Cancer 2007, 7:41 http://www.biomedcentral.com/1471-2407/7/41
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